Ista Pharmaceuticals Inc.
- Share via
The Irvine developer of products to treat eye disease reported a third-quarter net loss of $5.5 million, or 70 cents a share, compared with a net loss of $2.8 million, or $1.84 a share, for the same period last year. No revenue was reported.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
